NEW YORK--(BUSINESS WIRE)--IgG1 monoclonal antibodies developed by ImClone Systems Incorporated (NASDAQ: IMCL) were the focus of 44 total presentations at the recently concluded 98th Annual Meeting of the American Association for Cancer Research (AACR), including seven oral presentations and 37 posters.
